Sanjiv Patel Biography and Net Worth

President & Chief Executive Officer of Relay Therapeutics

Sanjiv Patel brings to Relay Therapeutics more than 20 years of life sciences industry experience. Prior to Relay Therapeutics, Sanjiv was at Allergan for more than a decade, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading global strategic marketing for all franchises and general management of Allergan’s fastest growth geographic region, the emerging markets. Sanjiv was most recently part of Allergan’s executive team as chief strategy officer, where he was at the center of some of the industry’s largest transactions. His work with the senior leadership team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities.

Prior to Allergan, Sanjiv was a management consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service.

Sanjiv holds an MBA from INSEAD, MBBS from the University of London and a M.A. in neurosciences from Cambridge University.

What is Sanjiv Patel's net worth?: The estimated net worth of Sanjiv Patel is at least $5.63 million as of November 3rd, 2025. Dr. Patel owns 703,215 shares of Relay Therapeutics stock worth more than $5,625,720 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Patel may own. Additionally, Dr. Patel receives an annual salary of $1,080,000.00 as President & Chief Executive Officer at Relay Therapeutics. Learn More about Sanjiv Patel's net worth.
How old is Sanjiv Patel?: Dr. Patel is currently 50 years old. There are 5 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. David Elliot Shaw Ph.D., Founder, who is 73 years old. Learn More on Sanjiv Patel's age.
What is Sanjiv Patel's salary?: As the President & Chief Executive Officer of Relay Therapeutics, Inc., Dr. Patel earns $1,080,000.00 per year. The highest earning executive at Relay Therapeutics is Dr. Donald A. Bergstrom M.D., Ph.D., President of Research & Development, who commands a salary of $1,370,000.00 per year. Learn More on Sanjiv Patel's salary.
How do I contact Sanjiv Patel?: The corporate mailing address for Dr. Patel and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Sanjiv Patel's contact information.
Has Sanjiv Patel been buying or selling shares of Relay Therapeutics?: During the last quarter, Sanjiv Patel has sold $434,511.00 in shares of Relay Therapeutics stock. Most recently, Sanjiv Patel sold 62,073 shares of the business's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $7.00, for a transaction totalling $434,511.00. Following the completion of the sale, the chief executive officer now directly owns 703,215 shares of the company's stock, valued at $4,922,505. Learn More on Sanjiv Patel's trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), Sanjiv Patel (President & Chief Executive Officer), Andy Porter (Insider), and Peter Rahmer (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 33 times. They sold a total of 968,861 shares worth more than $4,432,693.30. The most recent insider tranaction occured on November, 3rd when CEO Sanjiv Patel sold 62,073 shares worth more than $434,511.00. Insiders at Relay Therapeutics own 4.9% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 11/3/2025.

Sanjiv Patel Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/3/2025	Sell	62,073	$7.00	$434,511.00	703,215
7/9/2025	Sell	61,379	$3.57	$219,123.03	765,288
4/23/2025	Sell	61,422	$2.97	$182,423.34	821,667
2/13/2025	Sell	75,324	$3.70	$278,698.80	883,089
2/11/2025	Sell	140,182	$3.85	$539,700.70	625,948
1/22/2025	Sell	125,000	$4.80	$600,000.00	324,548
12/16/2024	Sell	100,000	$5.00	$500,000.00	574,548
7/26/2024	Sell	36,706	$9.07	$332,923.42	766,130
2/8/2023	Sell	14,000	$20.98	$293,720.00
1/18/2023	Sell	28,000	$20.87	$584,360.00	254,554
11/10/2022	Sell	28,000	$20.00	$560,000.00	254,554
11/8/2022	Sell	14,000	$20.18	$282,520.00	254,554
10/12/2022	Sell	14,000	$21.18	$296,520.00	254,554
9/14/2022	Sell	14,000	$23.47	$328,580.00	254,554
4/13/2022	Sell	28,000	$31.95	$894,600.00	253,740

Sanjiv Patel Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $8.00

$7.69

$8.09

50 Day Range

MA: $6.66

$5.17

$8.17

2 Week Range

Now: $8.00

$1.77

$8.36

Volume

1,205,788 shs

Average Volume

2,138,458 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Sanjiv Patel Biography and Net Worth

What is Sanjiv Patel's net worth?

How old is Sanjiv Patel?

What is Sanjiv Patel's salary?

How do I contact Sanjiv Patel?

Has Sanjiv Patel been buying or selling shares of Relay Therapeutics?

Who are Relay Therapeutics' active insiders?

Are insiders buying or selling shares of Relay Therapeutics?